{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T12:36:38Z","timestamp":1770899798855,"version":"3.50.1"},"reference-count":113,"publisher":"Informa UK Limited","issue":"12","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1517\/13543784.2014.944640","type":"journal-article","created":{"date-parts":[[2014,7,26]],"date-time":"2014-07-26T00:52:44Z","timestamp":1406335964000},"page":"1671-1686","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["Phase II drugs under investigation for allergic conjunctivitis"],"prefix":"10.1517","volume":"23","author":[{"given":"Monica","family":"Baiula","sequence":"first","affiliation":[{"name":"University of Bologna, Department of Pharmacy and Biotechnology (FaBiT)","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santi","family":"Spampinato","sequence":"additional","affiliation":[{"name":"University of Bologna, Department of Pharmacy and Biotechnology (FaBiT)","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2014,7,25]]},"reference":[{"key":"e_1_3_1_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.10.042"},{"key":"e_1_3_1_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0b013e3283303e2e"},{"key":"e_1_3_1_5_1","doi-asserted-by":"publisher","DOI":"10.1027\/0838-1925.19.S1.4"},{"key":"e_1_3_1_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-009-0042-1"},{"key":"e_1_3_1_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0b013e32834a9676"},{"key":"e_1_3_1_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-3-67"},{"key":"e_1_3_1_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/msj.20291"},{"key":"e_1_3_1_10_1","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2013.34.3612"},{"key":"e_1_3_1_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2011-301376"},{"key":"e_1_3_1_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2007.11.001"},{"key":"e_1_3_1_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2011.02272.x"},{"key":"e_1_3_1_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-008-0005-y"},{"key":"e_1_3_1_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clae.2009.08.002"},{"key":"e_1_3_1_16_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2012.00203"},{"key":"e_1_3_1_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2013.07.019"},{"key":"e_1_3_1_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/02713680490503750"},{"key":"e_1_3_1_19_1","first-page":"932","article-title":"Eosinophil cationic protein as a marker for assessing the efficacy of tacrolimus ophthalmic solution in the treatment of atopic keratoconjunctivitis","volume":"17","author":"Wakamatsu TH","year":"2011","unstructured":"Wakamatsu TH, Tanaka M, Satake Y, et al. Eosinophil cationic protein as a marker for assessing the efficacy of tacrolimus ophthalmic solution in the treatment of atopic keratoconjunctivitis. Mol Vis 2011;17:932-8","journal-title":"Mol Vis"},{"key":"e_1_3_1_20_1","first-page":"9","article-title":"Drugs for allergic disorders","volume":"9","year":"2010","unstructured":"Anonymous Drugs for allergic disorders. Treat Guide Med Lett 2010;9:9-18","journal-title":"Treat Guide Med Lett"},{"key":"e_1_3_1_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2008.07.007"},{"key":"e_1_3_1_22_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200565020-00004"},{"key":"e_1_3_1_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(02)85045-7"},{"key":"e_1_3_1_24_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0420.2000.078s230042.x"},{"key":"e_1_3_1_25_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S13479"},{"key":"e_1_3_1_26_1","doi-asserted-by":"publisher","DOI":"10.2174\/187221311794474883"},{"key":"e_1_3_1_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2010.04.006"},{"key":"e_1_3_1_28_1","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2013.34.3671"},{"key":"e_1_3_1_29_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S15788"},{"key":"e_1_3_1_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2008.11.006"},{"key":"e_1_3_1_31_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1Q755"},{"issue":"14","key":"e_1_3_1_32_1","first-page":"1999","article-title":"Safety profile of bilastine: 2nd generation H1-antihistamines","volume":"16","author":"Scaglione F","year":"2012","unstructured":"Scaglione F. Safety profile of bilastine: 2nd generation H1-antihistamines. Eur Rev Med Pharmacol Sci 2012;16(14):1999-2005","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_3_1_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/archoto.2010.128"},{"key":"e_1_3_1_34_1","doi-asserted-by":"publisher","DOI":"10.1159\/000232571"},{"key":"e_1_3_1_35_1","unstructured":"Effect of different concentrations of 1334H on allergic conjunctivitis. 2011. Available from: http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01320553?term=1334h&rank=1"},{"key":"e_1_3_1_36_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.3.5.541"},{"key":"e_1_3_1_37_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079903125001794"},{"key":"e_1_3_1_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12138"},{"key":"e_1_3_1_39_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.87.10.1206"},{"key":"e_1_3_1_40_1","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200323050-00003"},{"key":"e_1_3_1_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3038.2004.00146.x"},{"key":"e_1_3_1_42_1","unstructured":"Evaluation of the safety and efficacy of Ketotifen 4.0% patch as compared to placebo patch Olopatadine 0.2% ophthalmic solution and artificial tears in the conjunctival allergen challenge (CAC) model of acute allergic conjunctivitis. 2009. Available from: http:\/\/www.clinicaltrials.gov\/ct2\/show\/study\/NCT00836485?term=nct00836485&rank=1"},{"key":"e_1_3_1_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2009.07.005"},{"key":"e_1_3_1_44_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0420.2003.00079.x"},{"key":"e_1_3_1_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0b013e32833dfa28"},{"key":"e_1_3_1_46_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ICL.0000092071.82938.46"},{"key":"e_1_3_1_47_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2008.0103"},{"key":"e_1_3_1_48_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2009.0087"},{"key":"e_1_3_1_49_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2014.884070"},{"key":"e_1_3_1_50_1","unstructured":"Study evaluating the efficacy of administration of cyclosporine (low dose and high dose) and prednisolone acetate compared to its components and vehicle in patients with allergic conjunctivitis. 2010. Available from: http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01120132?term=nct01120132&rank=1"},{"key":"e_1_3_1_51_1","unstructured":"Evaluation of efficacy of coadministration of FOV1101-00 and prednisolone acetate in patients with mild ongoing ocular allergic inflammation. 2009. Available from: http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00833495?term=nct00833495&rank=1"},{"key":"e_1_3_1_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2012.02556.x"},{"key":"e_1_3_1_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2011.03804.x"},{"key":"e_1_3_1_54_1","volume-title":"Allergen-specific immunotherapy for the treatment of allergic rhinoconjunctivitis and\/or asthma: comparative effectiveness review","author":"Lin SY","year":"2013","unstructured":"Lin SY, Erekosima N, Suarez-Cuervo C, et al. Allergen-specific immunotherapy for the treatment of allergic rhinoconjunctivitis and\/or asthma: comparative effectiveness review. Comparative Effectiveness Reviews, No. 111 Johns Hopkins University Evidence-based Practice Center Agency for Healthcare Research and Quality (US), Rockville, MD; 2013. Report No.: 13-EHC061-EF"},{"key":"e_1_3_1_55_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2013-0343"},{"key":"e_1_3_1_56_1","unstructured":"Study on pharmacodynamic parameter and tolerability with subcutaneous immunotherapy in grass pollen allergic patients. 2009. Available from: http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00857779?term=nct00857779&rank=1"},{"key":"e_1_3_1_57_1","unstructured":"Safety and tolerability of toleromune grass in grass allergic subjects with rhinoconjunctivitis. 2010. Available from: http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01166061?term=nct01166061&rank=1"},{"key":"e_1_3_1_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.08.036"},{"key":"e_1_3_1_59_1","unstructured":"Study of specific allergen immunotherapy in grass pollen allergic subjects with epicutanoeus allergen administration (ZU-SkinSIT-003). 2008. Available from: http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00777374?term=nct00777374&rank=1"},{"issue":"4","key":"e_1_3_1_60_1","first-page":"119","article-title":"Comparison of efficacy, safety and immunologic effects of subcutaneous and sublingual immunotherapy in birch pollinosis: a randomized study","volume":"39","author":"Mauro M","year":"2007","unstructured":"Mauro M, Russello M, Incorvaia C, et al. Comparison of efficacy, safety and immunologic effects of subcutaneous and sublingual immunotherapy in birch pollinosis: a randomized study. Eur Ann Allergy Clin Immunol 2007;39(4):119-22","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"e_1_3_1_61_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1398-9995.2003.00387.x"},{"key":"e_1_3_1_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)62726-3"},{"issue":"1","key":"e_1_3_1_63_1","first-page":"55","article-title":"Injective versus sublingual immunotherapy in Alternaria tenuis allergic patients","volume":"6","author":"Bernardis P","year":"1996","unstructured":"Bernardis P, Agnoletto M, Puccinelli P, et al. Injective versus sublingual immunotherapy in Alternaria tenuis allergic patients. J Investig Allergol Clin Immunol 1996;6(1):55-62","journal-title":"J Investig Allergol Clin Immunol"},{"key":"e_1_3_1_64_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.7646"},{"key":"e_1_3_1_65_1","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2001.118891"},{"key":"e_1_3_1_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.05.003"},{"key":"e_1_3_1_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2007.07.046"},{"key":"e_1_3_1_68_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2011.03835.x"},{"key":"e_1_3_1_69_1","unstructured":"Safety study of grass pollen-derived peptides to treat seasonal allergic rhinoconjunctivitis. 2009. Available from: http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00833066?term=nct00833066&rank=1"},{"key":"e_1_3_1_70_1","unstructured":"Safety of gpASIT+TM subcutaneously administered to hay fever patients with or without immunoregulating adjuvant. 2011. Available from: http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01506375?term=nct01506375&rank=1"},{"key":"e_1_3_1_71_1","doi-asserted-by":"publisher","DOI":"10.1038\/374546a0"},{"key":"e_1_3_1_72_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2005.072686"},{"key":"e_1_3_1_73_1","doi-asserted-by":"publisher","DOI":"10.1042\/CS20100425"},{"key":"e_1_3_1_74_1","doi-asserted-by":"publisher","DOI":"10.1002\/1521-4141(200007)30:7<1841::AID-IMMU1841>3.0.CO;2-E"},{"key":"e_1_3_1_75_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1325"},{"key":"e_1_3_1_76_1","unstructured":"Dose finding study with CYT003-QbG10 in patients with house dust mite allergy. 2008. Available from: http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00800332?term=cyt003-qbg10&rank=2"},{"key":"e_1_3_1_77_1","unstructured":"Study to investigate an immunomodulatory therapy in adult patients with perennial allergic rhinoconjunctivitis. 2007. Available from: http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00575003?term=cyt003-qbg10&rank=4"},{"key":"e_1_3_1_78_1","unstructured":"A study to investigate an immunomodulatory therapy in adult patients with perennial allergic rhinoconjunctivitis. 2007. Available from: http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00574223?term=cyt003-qbg10&rank=5"},{"key":"e_1_3_1_79_1","unstructured":"Effect of an allergen vaccine in patients with allergic rhino-conjunctivitis and asthma due to house dust mite allergy. 2005. Available from: http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00652223?term=cyt003-qbg10&rank=8"},{"key":"e_1_3_1_80_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2008.03191.x"},{"key":"e_1_3_1_81_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2011.03783.x"},{"key":"e_1_3_1_82_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2013.802773"},{"key":"e_1_3_1_83_1","doi-asserted-by":"publisher","DOI":"10.2174\/187221311794474883"},{"key":"e_1_3_1_84_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0300372101"},{"key":"e_1_3_1_85_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2010.0177"},{"key":"e_1_3_1_86_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-5598"},{"key":"e_1_3_1_87_1","first-page":"3208","article-title":"Eosinophil as a cellular target of the ocular anti-allergic action of mapracorat, a novel selective glucocorticoid receptor agonist","volume":"17","author":"Baiula M","year":"2011","unstructured":"Baiula M, Spart\u00e0 A, Bedini A, et al. Eosinophil as a cellular target of the ocular anti-allergic action of mapracorat, a novel selective glucocorticoid receptor agonist. Mol Vis 2011;17:3208-23","journal-title":"Mol Vis"},{"key":"e_1_3_1_88_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S62659"},{"key":"e_1_3_1_89_1","unstructured":"Study to assess the safety and efficacy of BOL-303242-X ophthalmic suspension in dry eye syndrome. 2010. Available from: http:\/\/www.clinicaltrials.gov\/ct2\/show\/study\/NCT01163643?term=nct01163643&rank=1"},{"key":"e_1_3_1_90_1","unstructured":"Mapracorat ophthalmic formulation in subjects with allergic conjunctivitis. 2011. Available from: http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01289431?term=mapracorat&rank=6"},{"key":"e_1_3_1_91_1","unstructured":"Mapracorat ophthalmic suspension 3% for the treatment of ocular inflammation and pain following cataract surgery. 2012. Available from: http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01591161?term=mapracorat&rank=3"},{"key":"e_1_3_1_92_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2007.117515"},{"key":"e_1_3_1_93_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2006.02498.x"},{"key":"e_1_3_1_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2012.07.001"},{"key":"e_1_3_1_95_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.121.5.615"},{"key":"e_1_3_1_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2010.07.004"},{"key":"e_1_3_1_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2013.04.006"},{"key":"e_1_3_1_98_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1000833"},{"issue":"6","key":"e_1_3_1_99_1","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1038\/mi.2013.7","article-title":"Resolvin D1 and aspirin-triggered resolvin D1 regulate histamine-stimulated conjunctival goblet cell secretion","volume":"6","author":"Li D","year":"2013","unstructured":"Li D, Hodges RR, Jiao J, et al. Resolvin D1 and aspirin-triggered resolvin D1 regulate histamine-stimulated conjunctival goblet cell secretion. Mucosal Immunol 2013;6(6):1119-30","journal-title":"Mucosal Immunol"},{"key":"e_1_3_1_100_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-012-0121-z"},{"key":"e_1_3_1_101_1","unstructured":"Evaluation of the onset and duration of action of RX-10045 in allergic conjunctivitis. Available from: http:\/\/www.clinicaltrials.gov\/ct2\/show\/study\/NCT01639846?term=RX-10045&rank=2"},{"key":"e_1_3_1_102_1","unstructured":"A study of RX-10045 in the treatment of dry eye disease. 2012. Available from: http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01675570?term=RX-10045&rank=1"},{"key":"e_1_3_1_103_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01825.x"},{"key":"e_1_3_1_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(01)01433-7"},{"key":"e_1_3_1_105_1","doi-asserted-by":"publisher","DOI":"10.1097\/00003226-200311000-00009"},{"key":"e_1_3_1_106_1","unstructured":"Efficacy\/safety of human plasminogen eye drop in ligneous conjunctivitis patients. 2012. Available from: http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01554956?term=human+plasminogen&rank=1"},{"issue":"10","key":"e_1_3_1_107_1","first-page":"2283","article-title":"Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease","volume":"42","author":"Solomon A","year":"2001","unstructured":"Solomon A, Dursun D, Liu Z, et al. Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Invest Ophthalmol Vis Sci 2001;42(10):2283-92","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_1_108_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1217996110"},{"key":"e_1_3_1_109_1","unstructured":"A single center study for the treatment of moderate to severe allergic conjunctivitis (EBI-005-AC-1). 2014. Available from: http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02082899?term=ebi-005&rank=3"},{"key":"e_1_3_1_110_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2007.05.017"},{"key":"e_1_3_1_111_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.09-5078"},{"key":"e_1_3_1_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.09.015"},{"key":"e_1_3_1_113_1","unstructured":"Efficacy study to evaluate the effectiveness of 3 concentrations of SAR 1118 in allergic conjunctivitis. 2009. Available from: http:\/\/www.clinicaltrials.gov\/ct2\/show\/study\/NCT00882687?term=lifitegrast&rank=5"},{"key":"e_1_3_1_114_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0707488"},{"key":"e_1_3_1_115_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.12042"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/13543784.2014.944640","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T11:57:49Z","timestamp":1770897469000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/13543784.2014.944640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,25]]},"references-count":113,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["10.1517\/13543784.2014.944640"],"URL":"https:\/\/doi.org\/10.1517\/13543784.2014.944640","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,25]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2014-07-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}